Tendon Study

RCT-01: Tendon Repair

In 2017, RepliCel completed a phase 1 human clinical trial of RCT-01 in patients with a chronically injured Achilles tendon. The study proved the product’s safety and provided very promising indications of the product’s potential efficacy in restoring patient function, pain and activity levels in addition to impacting measures tendon blood flow and structure.

We are currently working with our orthopedic advisors to finalize the design of a phase 2 clinical study to evaluate the product’s ability to accomplish for tendon problems what nothing else can do for some patients – notably regenerate degenerated tendon tissue to get eliminate patient pain and get patients back to doing what they love.

RCT-01 for Chronic Achilles Tendinopathy

Skin-Derived Fibroblasts for the Treatment of Refractory Achilles Tendinosis: Preliminary Short-Term

Skin-Derived Tenocyte-like Cells for the Treatment of Patellar Tendinopathy

Treatment of Lateral Epicondylitis Using Skin-Derived Tenocyte-like Cells

RCT-01 for Chronic Achilles Tendinopathy

Autologous Cell Treatment for Achilles Tendinosis: A Phase 1/11 Clinical Trial

Clinical Potential of Hair-Follicle Derived Mesenchymal Cells in Cell Therapy: Multiple Therapeutic